• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

金属蛋白酶组织抑制因子-1(TIMP-1)的第2位残基是其对基质金属蛋白酶亲和力和特异性的主要决定因素,但替代作用与底物相应P1'残基的作用不相关。

Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1' residue of substrate.

作者信息

Meng Q, Malinovskii V, Huang W, Hu Y, Chung L, Nagase H, Bode W, Maskos K, Brew K

机构信息

Department of Biochemistry and Molecular Biology, University of Miami School of Medicine, Miami, Florida 33101, USA.

出版信息

J Biol Chem. 1999 Apr 9;274(15):10184-9. doi: 10.1074/jbc.274.15.10184.

DOI:10.1074/jbc.274.15.10184
PMID:10187802
Abstract

The unregulated activities of matrix metalloproteinases (MMPs) are implicated in disease processes including arthritis and tumor cell invasion and metastasis. MMP activities are controlled by four homologous endogenous protein inhibitors, tissue inhibitors of metalloproteinases (TIMPs), yet different TIMPs show little specificity for individual MMPs. The large interaction interface in the TIMP-1.MMP-3 complex includes a contiguous region of TIMP-1 around the disulfide bond between Cys1 and Cys70 that inserts into the active site of MMP-3. The effects of fifteen different substitutions for threonine 2 of this region reveal that this residue makes a large contribution to the stability of complexes with MMPs and has a dominant influence on the specificity for different MMPs. The size, charge, and hydrophobicity of residue 2 are key factors in the specificity of TIMP. Threonine 2 of TIMP-1 interacts with the S1' specificity pocket of MMP-3, which is a key to substrate specificity, but the structural requirements in TIMP-1 residue 2 for MMP binding differ greatly from those for the corresponding residue of a peptide substrate. These results demonstrate that TIMP variants with substitutions for Thr2 represent suitable starting points for generating more targeted TIMPs for investigation and for intervention in MMP-related diseases.

摘要

基质金属蛋白酶(MMPs)的无节制活动与包括关节炎以及肿瘤细胞侵袭和转移在内的疾病过程有关。MMP的活性受四种同源内源性蛋白抑制剂——金属蛋白酶组织抑制剂(TIMPs)的控制,然而不同的TIMPs对单个MMPs的特异性很低。TIMP-1.MMP-3复合物中的大相互作用界面包括TIMP-1围绕Cys1和Cys70之间二硫键的一个连续区域,该区域插入到MMP-3的活性位点。对该区域苏氨酸2的15种不同取代的影响表明,该残基对与MMPs形成复合物的稳定性有很大贡献,并且对不同MMPs的特异性有主导影响。残基2的大小、电荷和疏水性是TIMP特异性的关键因素。TIMP-1的苏氨酸2与MMP-3的S1'特异性口袋相互作用,这是底物特异性的关键,但TIMP-1残基2中与MMP结合的结构要求与肽底物相应残基的结构要求有很大差异。这些结果表明,用其他氨基酸取代Thr2的TIMP变体是生成更具针对性的TIMP以用于研究和干预MMP相关疾病的合适起点。

相似文献

1
Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1' residue of substrate.金属蛋白酶组织抑制因子-1(TIMP-1)的第2位残基是其对基质金属蛋白酶亲和力和特异性的主要决定因素,但替代作用与底物相应P1'残基的作用不相关。
J Biol Chem. 1999 Apr 9;274(15):10184-9. doi: 10.1074/jbc.274.15.10184.
2
Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases 1 (TIMP-1) locates an inhibitory region for matrix metalloproteinases.人金属蛋白酶组织抑制剂1(TIMP-1)氨基末端结构域的突变研究确定了基质金属蛋白酶的抑制区域。
J Biol Chem. 1997 Aug 29;272(35):22086-91. doi: 10.1074/jbc.272.35.22086.
3
Engineering of selective TIMPs.
Ann N Y Acad Sci. 1999 Jun 30;878:1-11. doi: 10.1111/j.1749-6632.1999.tb07670.x.
4
Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition.苏氨酸98,金属蛋白酶组织抑制剂(TIMP)-1在识别金属蛋白酶过程中的关键残基。
J Biol Chem. 2004 Apr 23;279(17):17562-9. doi: 10.1074/jbc.M312589200. Epub 2004 Jan 20.
5
Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors.限制金属蛋白酶组织抑制剂-1 N 结构域的特异性;明胶酶选择性抑制剂
Protein Sci. 2007 Sep;16(9):1905-13. doi: 10.1110/ps.072978507. Epub 2007 Jul 27.
6
Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.终末期扩张型心肌病患者左心室心肌中基质金属蛋白酶活性增加及选择性上调。
Circulation. 1998 May 5;97(17):1708-15. doi: 10.1161/01.cir.97.17.1708.
7
Matrix metalloproteinases and their inhibitors in gastric cancer.胃癌中的基质金属蛋白酶及其抑制剂
Gut. 1998 Dec;43(6):791-7. doi: 10.1136/gut.43.6.791.
8
Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase-1.基质金属蛋白酶-1催化结构域与金属蛋白酶组织抑制剂-1抑制结构域复合物的晶体结构。
J Biol Chem. 2007 Jan 5;282(1):364-71. doi: 10.1074/jbc.M607625200. Epub 2006 Oct 18.
9
Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2.人基质金属蛋白酶-2和-9与金属蛋白酶组织抑制剂(TIMP)-1和TIMP-2结合的动力学分析。
J Biol Chem. 1997 Nov 21;272(47):29975-83. doi: 10.1074/jbc.272.47.29975.
10
[Expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in joint tissues of rapidly destructive coxarthropathy (RDC), analyzed by immunohistochemical study].[通过免疫组织化学研究分析快速破坏性髋关节炎(RDC)关节组织中基质金属蛋白酶(MMPs)和金属蛋白酶组织抑制剂(TIMPs)的表达]
Ryumachi. 1997 Oct;37(5):688-95.

引用本文的文献

1
The Role of Extracellular Matrix in Human Neurodegenerative Diseases.细胞外基质在人类神经退行性疾病中的作用。
Int J Mol Sci. 2022 Sep 21;23(19):11085. doi: 10.3390/ijms231911085.
2
Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Echinoderms: Structure and Possible Functions.棘皮动物中的基质金属蛋白酶和金属蛋白酶组织抑制剂:结构和可能的功能。
Cells. 2021 Sep 6;10(9):2331. doi: 10.3390/cells10092331.
3
Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics.金属蛋白酶及其抑制剂:开发新型治疗药物的潜力。
Cells. 2020 May 25;9(5):1313. doi: 10.3390/cells9051313.
4
The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma.基质金属蛋白酶抑制剂的复兴:超越教条。
Cells. 2019 Aug 27;8(9):984. doi: 10.3390/cells8090984.
5
Directed evolution of the metalloproteinase inhibitor TIMP-1 reveals that its N- and C-terminal domains cooperate in matrix metalloproteinase recognition.金属蛋白酶抑制剂 TIMP-1 的定向进化揭示其 N-端和 C-端结构域在基质金属蛋白酶识别中协同作用。
J Biol Chem. 2019 Jun 14;294(24):9476-9488. doi: 10.1074/jbc.RA119.008321. Epub 2019 Apr 30.
6
Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.基质金属蛋白酶、血管重塑与血管疾病
Adv Pharmacol. 2018;81:241-330. doi: 10.1016/bs.apha.2017.08.002. Epub 2017 Sep 19.
7
Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.基质金属蛋白酶抑制剂作为无节制组织重塑和病理紊乱中的研究及治疗工具
Prog Mol Biol Transl Sci. 2017;148:355-420. doi: 10.1016/bs.pmbts.2017.04.003. Epub 2017 May 10.
8
Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer.基质金属蛋白酶抑制在乳腺癌中的治疗潜力
J Cell Biochem. 2017 Nov;118(11):3531-3548. doi: 10.1002/jcb.26185. Epub 2017 Jul 17.
9
Matrix Metalloproteinases in Remodeling of Lower Extremity Veins and Chronic Venous Disease.基质金属蛋白酶在下肢静脉重塑及慢性静脉疾病中的作用
Prog Mol Biol Transl Sci. 2017;147:267-299. doi: 10.1016/bs.pmbts.2017.02.003. Epub 2017 Mar 21.
10
Biochemical and Biological Attributes of Matrix Metalloproteinases.基质金属蛋白酶的生化及生物学特性
Prog Mol Biol Transl Sci. 2017;147:1-73. doi: 10.1016/bs.pmbts.2017.02.005. Epub 2017 Mar 22.